EUVIMEDEUVIMED entdecken
MetaanalyseSystematische Übersicht

Efficacy and Safety of Programmed Death-1 (PD-1)/Programmed Death-Ligand 1 (PD-L1) Checkpoint Inhibitors in Patients With Metastatic Castration-resistant Prostate Cancer: A Systematic Review and Meta-analysis

X Hong, Y Zhang, Z Chi, Q Xu, W Lin, Y Huang, T Lin, Y Zhang

Clinical Oncology · 2024-01 · 36 (1) · e20-e30

DOI: 10.1016/j.clon.2023.11.034 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Clinical Oncology, 2024-01. Verfasst von X Hong und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, PR China; Department of Urology, Shantou Central Hospital, S…. Hauptthemen laut MEDLINE: Programmed Cell Death 1 Receptor, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 37 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIMS: The aim of this systematic review with meta-analysis was to evaluate the efficacy and safety of programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) checkpoint inhibitors in patients with metastatic castration-resistant prostate cancer (mCRPC). MATERIALS AND METHODS: We searched PubMed, Embase and Cochrane Library until 1 July 2022 for mCRPC trials testing PD-1/PD-L1 checkpoint inhibitors. We measured the efficacy and safety using overall survival, progression-free survival (PFS), overall response rates (ORR), prostate-specific antigen (PSA) response rate or treatment-related adverse events (TRAEs). When possible, data were meta-analysed. RESULTS: Thirteen studies involving 2533 participants were included in this meta-analysis. The pooled hazard ratio for overall survival was 0.81 (95% confidence interval 0.42-1.20, I2 = 80.3%, PHeterogeneity<0.001) and for PFS was 0.65 (95% confidence interval 0.38-0.92, I2 = 72.2%, PHeterogeneity = 0.013). Furthermore, better ORR (relative risk = 2.77, 95% confidence interval 1.25-6.13, I2 = 0%, PHeterogeneity = 0.699) was found in PD-L1-expressing tumours. However, no statistical trends between PD-L1 status on PSA response rate (relative risk = 0.79, 95% confidence interval 0.5-1.25, I2 = 0%, PHeterogeneity = 0.953) and tumour mutational burden on ORR (relative risk = 2.53, 95% confidence interval 0.49-13.12, I2 = 74.5%, PHeterogeneity = 0.02) were observed. The pooled proportions of TRAEs and ≥ grade 3 TRAEs were 85.1% (95% confidence interval = 71.7-98.5%) and 31.6% (95% confidence interval = 18.9-44.4%), respectively. CONCLUSIONS: This meta-analysis showed that among selected populations of men with mCRPC, anti-PD-1/PD-L1 combination treatment may significantly increase the PFS benefits. However, overall survival in mCRPC warrants further testing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Programmed Cell Death 1 ReceptorProstatic Neoplasms, Castration-ResistantMaleHumansB7-H1 AntigenProstate-Specific AntigenLigandsImmune Checkpoint Inhibitors

Stichwörter der Autor:innen

Checkpoint inhibitorsmeta-analysisprogrammed cell death protein 1programmed death ligand 1prostate cancer

Substanzen

Programmed Cell Death 1 ReceptorB7-H1 AntigenProstate-Specific AntigenLigandsImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, PR China; Department of Urology, Shantou Central Hospital, Shantou, PR China.
  • Department of Urology, Shantou Central Hospital, Shantou, PR China.
  • Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, PR China. Electronic address: lintx@mail.sysu.edu.cn.
  • Department of Urology, Shantou Central Hospital, Shantou, PR China. Electronic address: zhang_yonghai@126.com.

Zitieren

APA

Hong, X., Zhang, Y., Chi, Z., Xu, Q., Lin, W., Huang, Y., Lin, T., & Zhang, Y. (2024). Efficacy and Safety of Programmed Death-1 (PD-1)/Programmed Death-Ligand 1 (PD-L1) Checkpoint Inhibitors in Patients With Metastatic Castration-resistant Prostate Cancer: A Systematic Review and Meta-analysis. Clinical Oncology, 36(1), e20-e30. https://doi.org/10.1016/j.clon.2023.11.034

Vancouver

Hong X, Zhang Y, Chi Z, Xu Q, Lin W, Huang Y, et al. Efficacy and Safety of Programmed Death-1 (PD-1)/Programmed Death-Ligand 1 (PD-L1) Checkpoint Inhibitors in Patients With Metastatic Castration-resistant Prostate Cancer: A Systematic Review and Meta-analysis. Clinical Oncology. 2024;36(1):e20-e30. doi:10.1016/j.clon.2023.11.034

BibTeX
@article{Hong2024,
  author = {Hong, X and Zhang, Y and Chi, Z and Xu, Q and Lin, W and Huang, Y and Lin, T and Zhang, Y},
  title = {Efficacy and Safety of Programmed Death-1 (PD-1)/Programmed Death-Ligand 1 (PD-L1) Checkpoint Inhibitors in Patients With Metastatic Castration-resistant Prostate Cancer: A Systematic Review and Meta-analysis},
  journal = {Clinical Oncology},
  year = {2024},
  volume = {36},
  number = {1},
  pages = {e20--e30},
  doi = {10.1016/j.clon.2023.11.034}
}
Kostenlos starten →